China's Brii jumps most in 4-1/2 months on COVID therapy tie-up with Sinopharm

Brii Biosciences

30/03/2022 04:56

** Shares of Brii Biosciences Ltd  2137.HK  jump as much as
23.3% to HK$11.66, the biggest intraday percentage gain since
Nov 15
    ** Stock of the infectious diseases therapies developer hit
the highest since March 21, extending gains for a second
session; stock is fifth-biggest percentage gainer on the Hong
Kong bourse
    ** Beijing-based Brii says it is partnering with China
state-owned pharmaceutical distribution group Sinopharm Holding
to accelerate the accessibility of the firm's combination
therapy to help more COVID-19 patients in China  urn:newsml:reuters.com:*:nFWN2VW0WQ
    ** Says the partnership will advance stockpiling,
distribution and regional access of Brii's neutralizing
monoclonal antibody therapy, the amubarvimab/romlusevimab
combination, to contribute to the prevention and control of
COVID-19 pandemic in the mainland 
    ** Says it has received purchase intention and stockpiling
requests from near 20 provincial Health Commissions and over 100
healthcare institutions and distribution companies, and it is
preparing for the production 
    ** The Hang Seng Commerce & Industry Index  .HSNC  rises 1%
and Hong Kong's healthcare index  .HSCIH  jumps 1.7%
    ** The Hang Seng Composite Index  .HSCI  climbs 1.3% and the
benchmark Hang Seng Index  .HSI  gains 1.2%
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))